Abstract
Two case studies in nonlinear mixed effects modeling are presented. The first case is development of a pharmacodynamic model with the acetylcholinesterase inhibitor zifrosilone. The second case study is the development and validation of a pharmacokinetic model for tobramycin in patients with varying degrees of renal function. All aspects of modeling are explored in the second case study: development of the structural model, covariate screening, covariate model development, examination of goodness of fit, influence analysis, validation through a combination of internal and external techniques, and answering various “what-if” questions through the use of simulation.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aarons L, Vozeh S, Wenk M, Weiss P, and Follath F. Population pharmacokinetics of tobramycin. British Journal of Clinical Pharmacology 1989; 38: 305-314.
Cockcroft DW and Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
Cutler NR, Seifert RD, Schleman MM, Sramek JJ, Szylleyko OJ, Howard DR, Barchowsky A, Wardle TS, and Brass EP. Acetylcholinesterase inhibition by zifrosilone: pharmacokinetics and pharmacodynamics. Clinical Pharmacology and Therapeutics 1995; 58: 54-61.
DuBois D and DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Archives of Internal Medicine 1916; 17: 863-871.
Jernigan AD, Hatch RC, and Wilson RC. Pharmacokinetics of tobramycin in cats. American Journal of Veterinary Research 1988; 49: 608-612.
Krishna S, Nagaraja NV, Planche T, Agbenyega T, Bedo-Addo G, Ansong A, Owusu-Ofori A, Shroads AL, Henderson G, Hutson A, Derendorf H, and Stacpoole PW. Population pharmacokinetics of intramuscular quinine in children with severe malaria. Antimicrobial Agents and Chemotherapy 2001; 45: 1803-1809.
Mager DE, Wyska E, and Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metabolism and Disposition 2003; 31: 510-519.
Naber KG, Westenfelder SR, and Madsen PO. Pharmacokinetics of the aminoglycoside antibiotic tobramycin in humans. Antimicrobial Agents and Chemotherapy 1973; 3: 469-473.
Sahota, T., Buil, N., Hara, K., and Della Pasqua, O. E. The chicken and the egg in interoccasion variability. Presented at Population Approach Group in Europe (PAGE), Berlin, Germany; 2010.
Swabb EA, Singhvi SM, Leitz MA, Frantz M, and Sugerman A. Metabolism and pharmacokinetics of aztreonam in healthy subjects. Antimicrobial Agents and Chemotherapy 1983; 24: 394-400.
Winslade NE, Adelman MH, Evans EJ, and Schentag JJ. Single-dose accumulation pharmacokinetics of tobramycin and netilmicin in normal volunteers. Antimicrobial Agents and Chemotherapy 1987; 31: 605-609.
Xuan D, Lu JF, Nicolau DP, and Nightingale CH. Population pharmacokinetics of tobramycin in hospitalized patients receiving once-daily dosing regimen. International Journal of Antimicrobial Agents 2000; 15: 185-191.
Recommended Reading
De Alwis DP, Aarons L, Palmer JL. Population pharmacokinetics of ondansetron: A covariate analysis. British Journal of Clinical Pharmacology 1998; 46: 117-125.
Gieschke R, Burger H-U, Reigner B, Blesch KS, Steimer J-L. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. British Journal of Clinical Pharmacology 2003; 55: 252-263.
Gisleskog PO, Hermann D, Hammarlund-Adenaes M, Karlsson MO. Validation of a population pharmacokinetic/pharmacodynamic model for 5α-reductase inhibitors. European Journal of Pharmaceutical Sciences 1999; 8: 291-299.
Kerbusch T, Wahlby U, Milligan PA, Karlsson MO. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. British Journal of Clinical Pharmacology 2003; 56: 639-652.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Bonate, P.L. (2011). Nonlinear Mixed Effects Models: Case Studies. In: Pharmacokinetic-Pharmacodynamic Modeling and Simulation. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-9485-1_9
Download citation
DOI: https://doi.org/10.1007/978-1-4419-9485-1_9
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-9484-4
Online ISBN: 978-1-4419-9485-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)